Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients

BACKGROUND: Metastatic renal cell carcinoma (mRCC) prognostic models may be improved by incorporating treatment-induced toxicities. METHODS: In sunitinib-treated mRCC patients (N=770), baseline prognostic factors and treatment-induced toxicities (hypertension (systolic blood pressure ⩾140 mm Hg), ne...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Br J Cancer
Autori principali: Donskov, Frede, Michaelson, M Dror, Puzanov, Igor, Davis, Mellar P, Bjarnason, Georg A, Motzer, Robert J, Goldstein, David, Lin, Xun, Cohen, Darrel P, Wiltshire, Robin, Rini, Brian I
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group 2015
Soggetti:
Translational Therapeutics
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4705883/
https://ncbi.nlm.nih.gov/pubmed/26492223
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2015.368
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi